Prognosis

A mesothelioma diagnosis comes with many important questions. Perhaps the most crucial question is – what is the prognosis? In fact, the prognosis of mesothelioma varies depending on a number of variables. These variables include:

1. The patient – their age, biology, and state of health
2. The cancer – has the mesothelioma spread or is it localized when it is diagnosed and what is the cell type
3. The treatment or treatments selected
4. The expertise of the treatment team (doctors and other clinicians)

The Patient’s Health

A patient’s general state of health is an important prognostic factor in fighting any disease and mesothelioma is no exception. In addition, a patient’s biology or physiology also plays a role. For example, will chemotherapy work or can it be tolerated? Does the patient have a heart condition so that surgery is not an option? How will the patient’s biology interact with the treatment? The answers to these questions can all play a role in the prognosis.

The Cancer

The spread or lack of spread of the cancer is also an important factor. If mesothelioma is localized it can be easier to treat. In fact, surgery is usually only an option if the cancer has not metastasized. If it has spread then treatment options may be more limited. In addition, there are three cell types of mesothelioma – epithelioid, biphasic, and sacramatoid. The first, epithelioid, often has the best prognosis of the three.

The Treatment

The treatment or therapies selected is also important. Patients can select from conventional therapies (radiation, chemo, and surgery), clinical trials or integrative or alternative modalities. Not every therapy works in every patient. There is an important connection between a person’s physiology, cancer and the treatments selected. The interchange or intersection of these three factors often dictate what the treatment outcome and prognosis will be. Unfortunately, it is often difficult to predict because how a tumor or a treatment acts in a patient’s body is often not known until after the fact.

The Doctors’ Expertise

The last factor is the expertise of your doctors or licensed care givers. How these people do their jobs can be a key factor in prognosis. Are the surgeons experienced with mesothelioma? For example, what is their mortality rate for surgery? The smallest rate bodes better than the highest rate. Also, what options can these treaters suggest? Do they only offer chemo or can they offer a wide range of different modalities and treatment options. All these factors play a role in the prognosis of mesothelioma.

Below are some more details about the prognosis for mesothelioma.

Prognosis of Pleural Mesothelioma

The prognosis of pleural mesothelioma with standard treatment is typically not great.   Median overall survival is a little over a year.  However, there are a number of factors that affect prognosis.

A number of studies have been performed over the years to determine what treatments are optimum for mesothelioma and what factors lead to a better prognosis. Below, we report on several of these.

In a September 2016 Austrian study, a total of 210 patients with malignant pleural mesothelioma were followed.

• 167 (79.5%) were men and 43 (20.5%) were women
• The average age was 67 at the time of diagnosis
• Asbestos exposure was confirmed in 109 (69.4%) patients
• The majority of patients had epithelioid cell type (67.2%)
• Sarcomatoid comprised 16 (7.6%)
• Biphasic was found in 28 patients (13.3%)
• In 25 patients, the cell type was not specified

Data about survival was available for 185 patients. The study found:

• Median overall survival was 19.1 months.
• Pleural mesothelioma patients with early-stage disease (stages I, II) had an overall survival of 26.4 months.
• Pleural mesothelioma patients with late-stage disease (stages III, IV) had an overall survival of 13.0 months .
• Patients with epithelioid cell type had overall survival of 25.1 months.
• Patients with sarcomatoid or biphasic cell type had overall survival of 10.2 months.
• There was no survival difference between males and females.
• There was no survival difference between patients below or above the age of 65 years.
• Survival was significantly better in patients undergoing surgery. However, these patients were significantly younger, had earlier-stage disease, better performance status, and more often had epithelioid subtype.

The study concluded that factors that indicated a better prognosis included: higher Karnofsky score, earlier stage disease, epithelioid cell type, and surgery within multimodality treatment.

• Management of malignant pleural mesothelioma – part 3 : Data from the Austrian Mesothelioma Interest Group (AMIG) database. Klikovits T, et al., Wien Klin Wochenschr. 2016 Sep;128(17-18):627-34.

Prognosis of Peritoneal Mesothelioma

The prognosis of peritoneal mesothelioma has become much better with the advent of surgery and HIPEC.  The following studies illustrate the improvements in prognosis over the last several years.

Peritoneal Mesothelioma Prognosis with Chemotherapy

In a 2011 Greek Study, chemotherapy was used to treat peritoneal mesothelioma patients.  Six patients with peritoneal mesothelioma were treated with 6 cycles of pemetrexed (500 mg/m2) and cisplatin (75 mg/m2). Chemotherapy was administered on an outpatient basis every 3 weeks. The estimated median overall survival was 24 months.

• Systemic chemotherapy with pemetrexed and cisplatin for malignant peritoneal mesothelioma: a single institution experience. Lainakis G, et al., Tumori. 2011 Jan-Feb;97(1):25-9.

Peritoneal Mesothelioma Prognosis with HIPEC

An April 2014 United States Study examined 65 patients with pleural mesothelioma who underwent surgery and HIPEC (hyperthermic intraperitoneal chemoperfusion) between 2001 and 2010.

What is HIPEC for Mesothelioma?

HIPEC is where heated chemotherapy is used to bath the surgical cavity putting the chemo in direct contact where the tumor cells remain.  The study found that overall mesothelioma survival was 46.2 months.  The study also found that although survival was better, there were side effects associated with this treatment approach that included:

• Six percent of the patients died within 60 days.
• Of the 65 patients, 91 % were admitted to the intensive care unit (ICU) postoperatively, with median hospital length of 12 days.
• A total of 12 patients (18 %) underwent reoperation: four patients (33 %) for enteric leak, 1 patient (8 %) for an intra-abdominal abscess, and seven patients (58%) for other reasons.

Factors that contributed to a poor prognosis included:

• Older patient
• More widespread tumors
• More aggressive cell type
• Incomplete surgery
• Post-operative infection

The study concluded that better prognosis is associated with patients who have the epithelioid cell type, lower volume of tumor, and more effective surgery (most tumor removed).

• Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Magge D., et al., Ann Surg Oncol. 2014 Apr;21(4):1159-65.

Next: Treatment

Related Posts

Shorter Mesothelioma Survival Again Linked to Higher PD-L1 Levels- Patients with the rarest mesothelioma subtypes tend to experience shorter mesothelioma survival. Now, new mesothelioma research suggests that may have something to do with a protein called PD-L1. French researchers studied the PD-L1 levels in the tumors of 214 mesothelioma patients. They compared the levels with each patient’s subtype and their treatment outcome.  The results may help explain cases of shorter mesothelioma survival, especially among patients with sarcomatoid or biphasic mesothelioma subtypes.  PD-L1 Levels and Shorter Mesothelioma Survival Programmed death ligand 1 (PD-L1) is one of the proteins that helps mesothelioma cells and other cancers “hide” from the immune system.  Normally, the immune system finds and destroys renegade cells. But if a patient’s mesothelioma tumor expresses higher amount of PD-L1, … Continue reading Shorter Mesothelioma Survival Again Linked to Higher PD-L1 Levels »

Mesothelioma Survival Rates Have Remained Flat for Decades- Mesothelioma survival rates have stayed steady for decades, even though treatments are improving. According to more than 25 years worth of data from the National Mesothelioma Virtual Bank, people with malignant mesothelioma live a median of 15 months. That number has changed little since 1990. Charting Mesothelioma Patients Over Time Researchers from several major US cancer centers compiled the new report. The goal was to chart mesothelioma survival rates over time and identify factors that impact them. The group evaluated mesothelioma survival rates from 888 cases of pleural and peritoneal mesothelioma in the NMVB. The NMVB houses information on more than 1400 mesothelioma cases diagnosed between 1990 and 2017. Overall mesothelioma survival rates stayed right around 15 months. But there … Continue reading Mesothelioma Survival Rates Have Remained Flat for Decades »

Adjuvant Radiotherapy Most Effective for Pleural Mesothelioma in Early Stages- New research shows adjuvant radiotherapy is most likely to help pleural mesothelioma patients in the early stages of the disease. By the time mesothelioma is at Stage III or Stage IV, adjuvant radiotherapy is unlikely to improve survival. Researchers at MD Anderson Cancer Center in Texas conducted the study on more than 2,500 pleural mesothelioma patients. Their results appear in the most recent issue of the Journal of Thoracic Disease. The study could help mesothelioma patients and doctors make more informed choices about their care. Defining the Stages of Pleural Mesothelioma The four stages of mesothelioma relate to the severity of the cancer and how far it has spread. In Stage I mesothelioma, the tumor is confined to the pleural … Continue reading Adjuvant Radiotherapy Most Effective for Pleural Mesothelioma in Early Stages »

Minimally Invasive Mesothelioma Diagnosis from Lung Fluid- Minimally invasive mesothelioma diagnosis with lung fluid may be just as effective as a tissue biopsy. That’s according to Australian mesothelioma researchers. Australia was once one of the biggest producers of asbestos and now has some of the highest mesothelioma rates in the world. It is also home to high-level mesothelioma research. In the latest study, scientists ran a meta-analysis comparing surgical biopsy with a minimally invasive mesothelioma diagnosis tool called cytology. Their conclusion is that surgery may not always be necessary to diagnose malignant mesothelioma. Tissue Versus Lung Fluid Malignant mesothelioma is a fatal cancer caused by exposure to asbestos. It is challenging to diagnose because the symptoms are often vague and similar to other less serious conditions. Doctors … Continue reading Minimally Invasive Mesothelioma Diagnosis from Lung Fluid »

Systemic Inflammation Linked to Shorter Mesothelioma Survival- Mesothelioma patients whose bodies respond to the illness with systemic inflammation are less likely to survive. Chinese researchers have linked a measure of systemic inflammation called SII to shorter survival in people with pleural mesothelioma. The new study involved 97 people with confirmed malignant mesothelioma. It suggests that SII could be a simple, non-invasive way to determine mesothelioma prognosis. What is SII? SII stands for “systemic immune-inflammation index”. When a body is under stress, such as when it is fighting mesothelioma, the innate immune system kicks into action. Certain kinds of white blood cells and proteins are released. The result is systemic inflammation. SII can be determined with a blood test. The test measures the levels of white blood cells … Continue reading Systemic Inflammation Linked to Shorter Mesothelioma Survival »

When Pleural and Peritoneal Mesothelioma Occur Together- Pleural and peritoneal mesothelioma rarely occur at the same time. But when they do, there is still hope for treatment. That message comes from a new study conducted at Columbia University and published in the Annals of Surgical Oncology. The researchers analyzed cases of patients diagnosed with both pleural and peritoneal mesothelioma at Columbia. They were looking for the factors that impacted their survival and the most effective ways to treat them. Comparing Pleural and Peritoneal Mesothelioma There are two primary types of malignant mesothelioma, the type of cancer most closely associated with asbestos exposure. The most common type is pleural mesothelioma. With this type, the first tumors show up on the membrane that surrounds the lungs (pleura). Chest pain, … Continue reading When Pleural and Peritoneal Mesothelioma Occur Together »

Mesothelioma Tumor Progression Can be Tracked With Blood Test- Italian researchers say it’s possible to monitor mesothelioma tumor progression with a simple blood test. They make their case in a Letter to the Editor in the latest edition of the Journal of Thoracic Oncology. The researchers say blood serum levels of the protein mesothelin correlate closely with tumor volume in malignant pleural mesothelioma patients. They are recommending that the blood test be used alongside CT to track mesothelioma tumor progression. The Importance of Monitoring Mesothelioma Tumor Progression Pleural mesothelioma is a rare cancer with a grim prognosis. Mesothelioma tumors tend to grow and spread quickly. Doctors have to carefully monitor mesothelioma tumor progression to tell if a treatment is working. Most mesothelioma patients have chemotherapy with Alimta (pemetrexed) and … Continue reading Mesothelioma Tumor Progression Can be Tracked With Blood Test »

Lower-Volume Centers Less Likely to Follow Mesothelioma Treatment Guidelines- Mesothelioma patients need to beware of low-volume centers that are less likely to follow mesothelioma treatment guidelines. That is the message from a new study based on data from the National Cancer Institute. The study was run by doctors at Cedars-Sinai Medical Center in Los Angeles. It shows that treatment centers that do not see a lot of mesothelioma cases are less likely to follow the life-saving mesothelioma treatment guidelines. As a result, patients treated in these lower-volume facilities tend to have shorter mesothelioma survival. What are the Mesothelioma Treatment Guidelines? Malignant pleural mesothelioma is a cancer that occurs on the membrane that surrounds the lungs. It is extremely rare and difficult to treat. Many hospitals and doctors never see … Continue reading Lower-Volume Centers Less Likely to Follow Mesothelioma Treatment Guidelines »

Metastatic Mesothelioma: Does Chemotherapy Work?- New research out of Pennsylvania suggested that not all people with metastatic mesothelioma will live longer with chemotherapy. Although chemotherapy is the primary treatment for malignant pleural mesothelioma, some types of metastatic mesothelioma appear to be less responsive than others. In some cases, the researchers say best supportive care may be a better option for preserving a patient’s quality of life. Three Mesothelioma Subtypes There are three histological subtypes of malignant pleural mesothelioma. The categories are based on how the cells look under a microscope. Cell type appears to influence how aggressive they are as metastatic mesothelioma. Cell type also factors into mesothelioma prognosis. Epithelioid mesothelioma is the most common cell type. Epithelioid cells tend to lack uniformity and may … Continue reading Metastatic Mesothelioma: Does Chemotherapy Work? »

New Tool Could Replace TNM for Predicting Pleural Mesothelioma Survival- A new visual tool could offer a better way to predict pleural mesothelioma survival after surgery than the current TNM staging system. That is the message from cancer researchers at China’s Peking University. The group conducted a study using a large US government database of information on pleural mesothelioma survival and treatment. They used the data to create a visual representation of pleural mesothelioma survival called a nomogram. Testing of the nomogram showed it was more accurate at predicting survival in patients who have mesothelioma surgery than the tool doctors normally use. Pleural Mesothelioma Survival and TNM The most popular method for “staging” cancer is called the TNM staging system. TNM stands for tumor node metastasis. With TNM, the further … Continue reading New Tool Could Replace TNM for Predicting Pleural Mesothelioma Survival »